ResMed (RMD) Competitors

ResMed has a net margin of 27.44% compared to Encompass Health's net margin of 10.04%. ResMed's return on equity of 25.35% beat Encompass Health's return on equity.

ResMed presently has a consensus target price of $286.18, suggesting a potential upside of 46.05%. Encompass Health has a consensus target price of $143.86, suggesting a potential upside of 37.80%. Given ResMed's higher probable upside, analysts plainly believe ResMed is more favorable than Encompass Health.

ResMed pays an annual dividend of $2.40 per share and has a dividend yield of 1.2%. Encompass Health pays an annual dividend of $0.76 per share and has a dividend yield of 0.7%. ResMed pays out 23.1% of its earnings in the form of a dividend. Encompass Health pays out 12.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. ResMed has increased its dividend for 13 consecutive years and Encompass Health has increased its dividend for 2 consecutive years. ResMed is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

55.0% of ResMed shares are held by institutional investors. Comparatively, 97.3% of Encompass Health shares are held by institutional investors. 0.7% of ResMed shares are held by insiders. Comparatively, 1.8% of Encompass Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, ResMed had 13 more articles in the media than Encompass Health. MarketBeat recorded 20 mentions for ResMed and 7 mentions for Encompass Health. Encompass Health's average media sentiment score of 1.34 beat ResMed's score of 1.07 indicating that Encompass Health is being referred to more favorably in the news media.

ResMed has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market. Comparatively, Encompass Health has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market.

ResMed has higher earnings, but lower revenue than Encompass Health. Encompass Health is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

63.5% of Hims & Hers Health shares are owned by institutional investors. Comparatively, 55.0% of ResMed shares are owned by institutional investors. 11.8% of Hims & Hers Health shares are owned by insiders. Comparatively, 0.7% of ResMed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Hims & Hers Health had 2 more articles in the media than ResMed. MarketBeat recorded 22 mentions for Hims & Hers Health and 20 mentions for ResMed. ResMed's average media sentiment score of 1.07 beat Hims & Hers Health's score of 0.83 indicating that ResMed is being referred to more favorably in the news media.

Hims & Hers Health presently has a consensus price target of $28.70, suggesting a potential upside of 9.32%. ResMed has a consensus price target of $286.18, suggesting a potential upside of 46.05%. Given ResMed's stronger consensus rating and higher possible upside, analysts plainly believe ResMed is more favorable than Hims & Hers Health.

ResMed has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Hims & Hers Health has a beta of 2.37, suggesting that its stock price is 137% more volatile than the broader market. Comparatively, ResMed has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market.

ResMed has a net margin of 27.44% compared to Hims & Hers Health's net margin of -0.56%. ResMed's return on equity of 25.35% beat Hims & Hers Health's return on equity.

55.0% of ResMed shares are owned by institutional investors. Comparatively, 82.1% of Medtronic shares are owned by institutional investors. 0.7% of ResMed shares are owned by insiders. Comparatively, 0.3% of Medtronic shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

ResMed presently has a consensus target price of $286.18, suggesting a potential upside of 46.05%. Medtronic has a consensus target price of $99.00, suggesting a potential upside of 21.23%. Given ResMed's stronger consensus rating and higher possible upside, equities analysts clearly believe ResMed is more favorable than Medtronic.

ResMed pays an annual dividend of $2.40 per share and has a dividend yield of 1.2%. Medtronic pays an annual dividend of $2.88 per share and has a dividend yield of 3.5%. ResMed pays out 23.1% of its earnings in the form of a dividend. Medtronic pays out 77.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. ResMed has increased its dividend for 13 consecutive years and Medtronic has increased its dividend for 49 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Medtronic had 62 more articles in the media than ResMed. MarketBeat recorded 82 mentions for Medtronic and 20 mentions for ResMed. ResMed's average media sentiment score of 1.07 beat Medtronic's score of 0.40 indicating that ResMed is being referred to more favorably in the media.

ResMed has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market. Comparatively, Medtronic has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market.

Medtronic has higher revenue and earnings than ResMed. ResMed is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

ResMed has a net margin of 27.44% compared to Medtronic's net margin of 13.20%. ResMed's return on equity of 25.35% beat Medtronic's return on equity.

Boston Scientific has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, ResMed has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market.

In the previous week, Boston Scientific had 12 more articles in the media than ResMed. MarketBeat recorded 32 mentions for Boston Scientific and 20 mentions for ResMed. ResMed's average media sentiment score of 1.07 beat Boston Scientific's score of 0.98 indicating that ResMed is being referred to more favorably in the news media.

89.1% of Boston Scientific shares are owned by institutional investors. Comparatively, 55.0% of ResMed shares are owned by institutional investors. 0.3% of Boston Scientific shares are owned by company insiders. Comparatively, 0.7% of ResMed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Boston Scientific has higher revenue and earnings than ResMed. ResMed is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.

ResMed has a net margin of 27.44% compared to Boston Scientific's net margin of 17.29%. ResMed's return on equity of 25.35% beat Boston Scientific's return on equity.

Boston Scientific presently has a consensus target price of $85.92, indicating a potential upside of 76.57%. ResMed has a consensus target price of $286.18, indicating a potential upside of 46.05%. Given Boston Scientific's stronger consensus rating and higher possible upside, analysts clearly believe Boston Scientific is more favorable than ResMed.